Cargando…

Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease

BACKGROUND: Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide. However, there are few studies of tiotropium bromide on sputum and sputum viscosity. To evaluate the effect of tiotropium bromide on mucus hypersecretion, a randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Suyun, Zhang, Caili, Yan, Zhijun, Fang, Qingqing, Gao, Xiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510842/
https://www.ncbi.nlm.nih.gov/pubmed/34650619
http://dx.doi.org/10.1155/2021/1341644
_version_ 1784582660752932864
author Yu, Suyun
Zhang, Caili
Yan, Zhijun
Fang, Qingqing
Gao, Xiwen
author_facet Yu, Suyun
Zhang, Caili
Yan, Zhijun
Fang, Qingqing
Gao, Xiwen
author_sort Yu, Suyun
collection PubMed
description BACKGROUND: Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide. However, there are few studies of tiotropium bromide on sputum and sputum viscosity. To evaluate the effect of tiotropium bromide on mucus hypersecretion, a randomized, double-blind controlled trial was performed. METHODS: 120 cases of patients with pulmonary function grade II were divided into two groups, which include the treatment group given tiotropium bromide powder inhalation (18 μg, inhalation, QD) and the control group given formoterol fumarate powder inhalation (12 μg, inhalation, BID) plus ambroxol hydrochloride tablets (60 mg, oral, TID). After 3 months of treatment, the pulmonary function and α(1)-acid glycoprotein (α(1)-AGP) in sputum were detected, and the changes of glycoprotein and Ca(2+) content were evaluated by Miller classification. RESULTS: Three patients (2 cases in the treatment group and 1 case in the control group) were dropped due to loss of follow-up, and 117 cases of patients were enrolled in this study. After 3 months of treatment, the sputum character score, α1-acid glycoprotein, Ca(2+) content, and lung function of the two groups were significantly improved; group comparison analyses revealed that there was no significant difference in the content of α(1)-AGP, Ca(2+) in sputum, and lung function between the two groups (P > 0.05), but the improvement of sputum properties was significant (P < 0.05), and the treatment group was better than the control group (t = −2.77; P = 0.007). CONCLUSIONS: Inhaled tiotropium bromide can effectively inhibit the mucus hypersecretion in stable COPD patients, improve the sputum properties and lung function of patients, and improve the quality of life of patients.
format Online
Article
Text
id pubmed-8510842
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85108422021-10-13 Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease Yu, Suyun Zhang, Caili Yan, Zhijun Fang, Qingqing Gao, Xiwen Comput Math Methods Med Research Article BACKGROUND: Patients with stable chronic obstructive pulmonary disease (COPD) have been observed to benefit from tiotropium bromide. However, there are few studies of tiotropium bromide on sputum and sputum viscosity. To evaluate the effect of tiotropium bromide on mucus hypersecretion, a randomized, double-blind controlled trial was performed. METHODS: 120 cases of patients with pulmonary function grade II were divided into two groups, which include the treatment group given tiotropium bromide powder inhalation (18 μg, inhalation, QD) and the control group given formoterol fumarate powder inhalation (12 μg, inhalation, BID) plus ambroxol hydrochloride tablets (60 mg, oral, TID). After 3 months of treatment, the pulmonary function and α(1)-acid glycoprotein (α(1)-AGP) in sputum were detected, and the changes of glycoprotein and Ca(2+) content were evaluated by Miller classification. RESULTS: Three patients (2 cases in the treatment group and 1 case in the control group) were dropped due to loss of follow-up, and 117 cases of patients were enrolled in this study. After 3 months of treatment, the sputum character score, α1-acid glycoprotein, Ca(2+) content, and lung function of the two groups were significantly improved; group comparison analyses revealed that there was no significant difference in the content of α(1)-AGP, Ca(2+) in sputum, and lung function between the two groups (P > 0.05), but the improvement of sputum properties was significant (P < 0.05), and the treatment group was better than the control group (t = −2.77; P = 0.007). CONCLUSIONS: Inhaled tiotropium bromide can effectively inhibit the mucus hypersecretion in stable COPD patients, improve the sputum properties and lung function of patients, and improve the quality of life of patients. Hindawi 2021-10-05 /pmc/articles/PMC8510842/ /pubmed/34650619 http://dx.doi.org/10.1155/2021/1341644 Text en Copyright © 2021 Suyun Yu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yu, Suyun
Zhang, Caili
Yan, Zhijun
Fang, Qingqing
Gao, Xiwen
Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title_full Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title_fullStr Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title_full_unstemmed Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title_short Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease
title_sort tiotropium bromide attenuates mucus hypersecretion in patients with stable chronic obstructive pulmonary disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510842/
https://www.ncbi.nlm.nih.gov/pubmed/34650619
http://dx.doi.org/10.1155/2021/1341644
work_keys_str_mv AT yusuyun tiotropiumbromideattenuatesmucushypersecretioninpatientswithstablechronicobstructivepulmonarydisease
AT zhangcaili tiotropiumbromideattenuatesmucushypersecretioninpatientswithstablechronicobstructivepulmonarydisease
AT yanzhijun tiotropiumbromideattenuatesmucushypersecretioninpatientswithstablechronicobstructivepulmonarydisease
AT fangqingqing tiotropiumbromideattenuatesmucushypersecretioninpatientswithstablechronicobstructivepulmonarydisease
AT gaoxiwen tiotropiumbromideattenuatesmucushypersecretioninpatientswithstablechronicobstructivepulmonarydisease